INTRODUCTION
Surgery has been, for many years, the mainstay of treatment of patients with advanced, resectable squamous cell carcinoma of the base of tongue; however, extensive resections of the base of tongue frequently resulted in significant speech and swallowing disabilities. The advent of chemotherapy in the treatment of other head and neck cancers, such as larynx cancer with a goal of organ preservation, has led to the adoption of this approach for cancers of other head and neck sites. The Veterans Affairs Laryngeal Cancer Study Group showed that induction chemotherapy followed by radiation, when compared to laryngectomy followed by radiation, provided organ preservation among two-thirds of patients without survival compromise. 1 More recently, it has been shown that concurrent administration of chemotherapy with radiation provides excellent organ preservation when compared with radiation alone for locally advanced larynx cancer. 2 Over the last decade, induction chemotherapy, concurrent chemoradiotherapy (CCR), and sequential therapy with induction and concurrent therapy have been evaluated in squamous cell carcinoma of the head and neck. At our institution, we have studied the use of organ preservation regimens for base of tongue cancer, with combinations of chemotherapy and radiation, since 1994.
Sequential therapy may show high rates of complete response (CR), but some believe the associated toxicity of treatment is not acceptable. However, several trials consisting of taxane-based induction chemotherapy followed by CCR have shown acceptable toxicities while maintaining the therapeutic effectiveness. Machtay et al. 3 showed that platinum and taxol-based induction and concurrent therapy for oropharynx cancer had a tolerable toxicity profile and maintained good overall survival (OS) rates. Similar results from other institutions have been reported using platinum-and/or taxane-based protocols. 4, 5 The TIP induction regimen used in the present study incorporates two of the most active agents in head and neck cancer (Taxol [Bristol-Myers Squibb, Princeton, NJ] and cisplatin). This regimen has shown success previously, the main potential toxicity of it is peripheral neuropathy that is dose dependent and seen more often when treatment is extended for up to six cycles. 6 However, with three or less cycles of induction chemotherapy, neuropathy would not be an expected major toxicity. We report here, the results of a cohort of 18 patients with stage III and IV base of tongue cancer that were treated with a regimen consisting of taxol and platinum-based induction chemotherapy followed by CCR. The primary objective of this study was to evaluate CR rate at the primary tumor site after completion of the sequential treatment plan. A secondary endpoint was to evaluate toxicity and tolerability of treatment.
MATERIALS AND METHODS

Eligibility and Design
This study included 18 consecutive biopsy proven cases of advanced squamous cell carcinoma of the base of tongue, stage III or IV, treated with sequential chemotherapy and CCR as described below. This group was part of a trial that also included patients with other primaries in the larynx and oropharynx. The protocol was IRB approved, and informed consent was obtained from all patients enrolled. Patients were excluded if they had previous chemotherapy or radiation therapy for head and neck cancer, if their life expectancies was less than 6 months, or had a history of other malignancies in the 5 years prior with the exception of cured basal cell or squamous cell carcinoma of the skin. All patients had a performance status of Ͻ2 using the ECOG scale, serum creatinine level of 1.5 mg/dL or less, white blood cell count greater than 3,500/mm 3 , platelet count of at least 100,000/mm, and hemoglobin of 12 g or greater at time of inclusion.
During the period of the study, an attempt was made to include in the treatment protocol every medically fit patient with base of tongue cancer. Those patients ineligible because of performance status or other reasons were offered alternative treatment usually with radiation alone. There were no eligible patients that were treated primarily with surgery. Therefore, we did not include those patients as a point of reference in this study, since their treatment was not assigned randomly.
Treatment
Induction chemotherapy was administered every 21 days for up to 3 courses before CCR. If the patient did not achieve at least partial response (PR) at the base of tongue primary after two cycles of induction, the patient was deemed a nonresponder and the third cycle was not allowed. Those patients receive a surgery and postoperative radiation. Patients showing clinical regression of the primary tumor with neck nodes that had regressed or were stable received the third induction cycle. Patients with a complete clinical response after two cycles proceeded to CCR without a third induction cycle.
Induction regimen. Each induction cycle consisted of Taxol (paclitaxel) 175 mg/m 2 administered over a 3-hour period, cisplatinum 60 mg/m 2 administered over the next 1 hour, followed by ifosfamide 1000 mg/m 2 given over 2 hours for the first day. Ifosfamide was repeated alone in the same dose on days 2 and 3. Mesna was given around each ifosfamide treatment (200 mg/m 2 before, 400 mg/m 2 4 hours after). This is referred to as TIP induction.
Concurrent chemoradiotherapy. Responders to induction went on to receive CCR with taxol 60 mg/m 2 over a 1-hour period and carboplatin at an area under the concentration-time curve of 1 given over 30 minutes. This was given weekly for 7 weeks. Chemotherapy was held if patients were found to have an absolute neutrophil count of less than 1,000 or platelet count of less than 100,000 during this period.
Patients were irradiated either daily in 1.8 to 2.0 Gy per day or elective twice-daily therapy delivering a cumulative daily dose of 2.4 to 2.6 Gy per day. Total dose delivered to gross disease was set at 74.0 to 82.0 Gy over a 6-to 8-week period. Spinal cord radiation dose was limited to 42 Gy. If necessary, weekly erythropoietin 40,000 u was allowable to maintain hemoglobin concentration above 12 g. Patients were encouraged to have percutaneous endoscopic gastrostomy (PEG) tube placement before CCR if they were unable to maintain adequate oral intake or had lost more than 10% of their preinduction weight.
Surgery. Patients with less than PR, defined as 50% decrease in the product of perpendicular diameters of the primary tumor, and those with progression of tumor would undergo surgery either 3 weeks after initiation of last chemotherapy cycle, or whenever the white blood count had stabilized. If patients did not show CR after completion of the CCR phase, surgery was performed between 4 and 8 weeks after final radiation, depending on mucosal/skin stability. Any patient with persistence of palpable lymph nodes in the neck after completion of CCR underwent neck dissection 4 to 6 weeks later. The lymph node levels involving presumed disease, as well as the two surrounding levels were removed. Surgery was also planned for patients having locoregional recurrence after CR.
Analysis. Records were analyzed for each patient and data were collected on patient demographics, tumor stage at diagnosis, and dates of significant treatment-related events. Each follow-up record was evaluated for each patient from the time of CR to the last follow-up as of July 1, 2007, looking for evidence of either recurrent disease or maintenance of disease-free status. Stable disease was defined as decrease of less than 50% or increase of less than 25% in products of diameters of measurable lesions with no new lesions appearing during the study. PR was defined as decrease of 50% or more in the sum of the products of diameters of measurable lesions for at least 1 month. CR was defined as complete disappearance of all objective evidence of disease for at least 1 month. Disease-free survival was defined as time from CR to either recurrence of disease in the base of tongue or development of metastatic disease. OS was defined as time from inclusion in the study to date of death. Quantitative toxicity grading was accomplished in some patients, but not all. Available toxicity grades were recorded, as well as overall incidence of toxicity attributable to treatment.
RESULTS
Patient Characteristics
Eighteen patients were enrolled in the protocol between November 1, 2001 and March 30, 2006. All patients were either stage III or IV at diagnosis, with a predominance being stage IV. Patient characteristics, including Tumor, Node, Metastasis staging, are shown in Table I .
Response to Treatment
Seventeen of 18 patients had at least a PR to induction therapy. Eight patients (44%) had a complete clinical response at the primary site after two cycles of induction and an additional four (22%) had complete clinical response at the primary after a third cycle of induction. Therefore, 12 of 18 patients (66%) had complete clinical response before the CCR phase of treatment. The remaining five patients had a complete clinical response after completion of the CCR portion of treatment. One patient was found to be a nonresponder after two cycles of induction chemotherapy. This patient went off the protocol as he refused surgical intervention and underwent radiation treatment. He eventually succumbed to disease. This data are shown in Table II .
Surgical Salvage
No patient required salvage surgery at the primary site. Neck dissections were performed in five of the 18 patients. These were done after the CCR phase for stable neck disease and 4 of 5 showed no evidence of metastatic disease. One had histopathological evidence of persistent nodal disease. This patient remains disease free at 43.0 months.
Local-Regional Control and Recurrence
The median follow-up for all patients is 29.6 months (range, 4.5-43.0 months). To date, 2 of 17 patients have been lost to follow-up due to moving out of the state. At last follow-up, all of the remaining 15 patients are alive, free of disease in the base of the tongue, and have not developed recurrence in the neck. One patient developed metastatic disease to the spine after being disease free for 29.6 months. All individual patient statistics are listed in Table III . Type of response seen after two induction cycles, then three induction cycles, and finally after CCR. Of the nine in partial response after two induction cycles, four were in complete response after three induction cycles, and the remaining five were in complete response after CCR.
CCR ϭ concurrent chemoradiotherapy. Individual patient data regarding the time span from diagnosis to initiation. No relationship was seen between number of induction cycles and survival rate. Patient number 9 developed spinal metastasis. Patients 12 and 13 were lost to follow-up after showing CR.
*The only patient with recurrent disease after initial concurrent chemoradiotherapy.
DFS ϭ disease-free survival; CR ϭ complete response.
Treatment Toxicity
The treatment was tolerated well by all patients with 17 of 18 (94%) completing both the induction and concurrent portions without interruption because of toxicity. Toxicities were documented, but not quantified in most cases. They are listed in Table IV . PEG tubes were placed in 15 patients (83%) with three patients (17%) necessitating permanent PEG tube use because of severe dysphagia and esophageal strictures.
DISCUSSION
Efficacy
All patients who had shown any response after two cycles of induction chemotherapy (94%) went on to a complete clinical response by at least the end of CCR. Although follow-up is brief, this CR has been sustained, with 13 patients being disease free for over 2 years after completing therapy. Similar protocols of induction chemotherapy followed by concurrent chemoradiation in patients with head and neck cancer have shown overall response rates ranging from 80% to 90% with CR rates ranging from 40% to 90%. 3, 7 Although these trials have larger numbers and are not base of tongue specific, the results provided here are similar with an overall response rate and CR rate of 94%. Many studies have similar diseasefree survival and OS rates. Comparative trials are listed in Table V. On evaluation, the single patient who developed spinal metastasis was noted to have an unusually long time interval between diagnosis and initiation of induction chemotherapy of 154 days. In all other cases, the mean time from diagnosis to initiation of treatment was 27 days (range, 7-59 days). It is possible that this delay is related to the development of metastatic disease in this patient.
Toxicity
Toxicity with sequential regimens remains a concern as patients are subjected to both the high doses of induction therapy and concurrent chemoradiotherapy. Often times, patients are required to take a reprieve or discontinue treatment completely because of adverse affects. After reviewing the treatment data, no delays in the protocol were found relating to toxicity. The TIP induction incorporates two of the most active agents in head and neck cancer (Taxol and cisplatin) while avoiding the mucosal toxicity of 5-FU used in many other regimens. This regimen has shown success previously, but was abandoned due to excessive peripheral neuropathy. 6 This article stated that patients developing peripheral neuropathy, and some developing grade 3, were found to fully resolve with cessation of treatment. They further noted a dose dependent relationship, and some participants received up to six cycles of TIP. In this protocol however, patients were treated with only two or three cycles of the TIP regimen as induction therapy. The secondary benefit from this was a more tolerable toxicity profile. While 3 of 18 patients (17%) developed neuropathy over the course of induction, it was found to be transient and did not cause treatment delays. Persistent side effects were related to CCR. Several patients (17%) were noted to require permanent PEG tubes due to unresolved dysphagia. Although this is not uncommon, this remains a setback for CCR. Alterations in radiation dosing may be feasible and the addition of biological agents to this regimen should be further studied to address this issue. Comparison of three similar sequential studies. Cmelak et al. and Machtay et al. conducted dual drug induction followed by CCR while Haddad et al. conducted a tri-drug induction followed by CCR. TIP data is from all patients initially enrolled in the study, including the non-responder who went off protocol.
CCR ϭ concurrent chemoradiotherapy.
CONCLUSION
The use of paclitaxel, ifosfamide, and cisplatinum for induction chemotherapy followed by concomitant paclitaxel and carboplatin with radiotherapy is effective treatment for stage III and IV squamous cell carcinoma of the base of tongue in patients who initially respond to the treatment. Although toxicity was not assessed in a quantitative manner, the induction and concurrent portions of therapy were well tolerated. Toxicity did not preclude delivery of any portion of the treatment protocol.
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